PAM SPECIALTY HOSPITAL OF DENVER
1. Target Overview & Investment Thesis
PAM SPECIALTY HOSPITAL OF DENVER is a 63-bed safety-net/medicaid heavy in DENVER, CO with $53.3M in net patient revenue and a 26.4% operating margin. The hospital serves a payer mix of 7.7% Medicare, 50.6% Medicaid, and 41.6% commercial.
Thesis: Turnaround. Our ML models identify $3.9M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 26.4% to 33.8% (+736bps).
| Net Revenue HCRIS | $53.3M |
| Current EBITDA COMPUTED | $14.1M |
| Operating Margin COMPUTED | 26.4% |
| Occupancy HCRIS | 89.3% |
| Revenue / Bed COMPUTED | $845K |
| Net-to-Gross HCRIS | 34.9% |
| Distress Probability ML | 50.7% |
2. Market Context & Competitive Position
CO has 108 Medicare-certified hospitals with a median operating margin of -3.6%. The target's margin of 26.4% places it above the state median. Among 41 size-comparable peers (32-126 beds), the median margin is -5.1%. The target performs in line with or above peers.
3. RCM Performance Analysis — Comparable Hospitals
Comps selected by bed count (32-126), prioritizing same-state peers. 41 hospitals in the comp set.
| Hospital | State | Beds | Revenue | Margin |
|---|---|---|---|---|
| PAM SPECIALTY HOSPITAL OF DENV (Target) | CO | 63 | $53.3M | 26.4% |
| CENTURA MERCY HOSPITAL | CO | 73 | $270.4M | 10.0% |
| CENTURA ST. ANTHONY NORTH HOSP | CO | 118 | $268.3M | 10.9% |
| UCHEALTH HIGHLANDS RANCH HOSPI | CO | 93 | $235.2M | -4.6% |
| CHCO - COLORADO SPRINGS | CO | 124 | $220.2M | -9.2% |
| COMMUNITY HOSPITAL | CO | 44 | $216.5M | -5.5% |
| VAIL VALLEY MEDICAL CENTER | CO | 54 | $214.4M | -28.1% |
| UCHEALTH LONGS PEAK HOSPITAL | CO | 83 | $181.8M | -1.7% |
| CENTURA AVISTA ADVENTIST HOSPI | CO | 108 | $181.3M | 8.4% |
4. Predicted Improvement Opportunities
Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $3.9M (736bps margin improvement).
| Lever | Current | Target | EBITDA Impact | Margin | Ramp |
|---|---|---|---|---|---|
| Net Collection Rate | 93.5% | 97.0% | $1.1M | +210bp | 18mo |
| Cost to Collect | 4.5% | 2.5% | $1.1M | +200bp | 12mo |
| Denial Rate Reduction | 12.0% | 6.5% | $1.1M | +198bp | 12mo |
| A/R Days Reduction | 5200.0% | 3800.0% | $648K | +122bp | 9mo |
| Clean Claim Rate | 88.0% | 96.0% | $34K | +6bp | 6mo |
5. EBITDA Bridge
| Current EBITDA | $14.1M |
| + RCM Uplift | +$3.9M |
| Pro Forma EBITDA | $18.0M |
| Current Margin | 26.4% |
| Pro Forma Margin | 33.8% |
| WC Released (1x) | $2.0M |
6. Returns Analysis — Scenario Matrix
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.
| Scenario | Entry | Exit | Equity In | Equity Out | MOIC | IRR |
|---|---|---|---|---|---|---|
| Base Case | 10.0x | 10.0x | $21.6M | $132.0M | 6.10x | 43.6% |
| Base (11x exit) | 10.0x | 11.0x | $21.6M | $152.2M | 7.03x | 47.7% |
| Bull Case | 9.0x | 11.0x | $19.5M | $172.2M | 8.84x | 54.6% |
| Bull (12x exit) | 9.0x | 12.0x | $19.5M | $193.6M | 9.94x | 58.3% |
| Bear Case | 11.0x | 10.0x | $23.8M | $105.4M | 4.43x | 34.6% |
| Bear (11x exit) | 11.0x | 11.0x | $23.8M | $123.6M | 5.19x | 39.0% |
7. Key Risks & Mitigants
| Severity | Risk Factor | Mitigant |
|---|---|---|
| Medium | Elevated Medicaid exposure (50.6%) | Medicaid reimburses below cost in most states. Mitigant: denial reduction lever has highest impact on Medicaid claims |
| High | Elevated distress probability | Model estimates 50.7% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk |
8. Data Sources & Methodology Appendix
Data Sources
- CMS HCRIS Cost Reports (Medicare-certified hospitals)
- CMS Medicare Utilization (DRG-level volumes)
- CMS Chronic Conditions (county-level disease prevalence)
- HCRIS multi-year trend data (financial time series)
Comparable Selection
- 41 hospitals with 32-126 beds
- Same-state prioritization (n=42)
- Comp margins: P25=-9.7% / P50=-5.1% / P75=4.6%
Bridge Methodology
- Targets: P75 of comparable peers (60% gap closure)
- Denial: avoidable share = 35% of delta × NPR
- AR: bad debt coefficient = $0.65 per day per $1K NPR
- NCR: 60% coefficient on collection rate improvement
- CDI: 0.75% of Medicare revenue per 0.01 CMI point
Returns Assumptions
- Leverage: 5.5x entry (84.6% debt / 15.4% equity)
- Organic growth: 3% annual EBITDA growth
- Debt paydown: 10% of principal per year
- Hold period: 5 years
Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.